Abstract 1588P
Background
Esophagectomy is a high-risk surgical procedure with significant postoperative morbidity and mortality. Anastomotic leakage is still one of the most serious complications after anterior resection for esophageal carcinoma. This study aimed to analyze the risk factors after minimally invasive cervical anastomosis of esophageal cancer and postoperative mortality.
Methods
This was a retrospective study of 312 minimally invasive cervical anastomosis of esophageal cancer in a single institute between 2013 and 2016. The anastomotic level and perioperative confounding factors were analyzed by univariate and multivariate logistic regression to identify potential risk factors for postoperative leakage.
Results
Total 312 patients were evaluated. Overall leak rate was 10.6%. In-hospital or 30-day mortality was 0%. Only 3 patients received intensive care unit due to postoperative complications and mean hospital stay was 14.22 (±7.70) days. Univariate analysis showed that the following variables were related to the incidence of anastomotic leakage: neoadjuvant chemotherapy before operation (p=0.007); body mass index (BMI) (p=0.000); diabetes (p=0.001); operation time (p=0.006). Multivariable analysis identified diabetes [P = 0.032, odds ratio (OR) 2.637, 95% confidence interval (CI): 1.087-6.393], BMI [P = 0.003, odds ratio (OR) 1.223, 95% confidence interval (CI): 1.070-1.399] and operation time [P = 0.033, odds ratio (OR) 1.012, 95% confidence interval (CI): 1.001-1.024] as the risk factors of anastomotic leakage.
Conclusions
Diabetes, operation time and BMI are independent prognostic factors for cervical anastomotic leakage of minimally invasive esophageal cancer. Cervical anastomotic leakage will not affect the short-term survival of the patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
M. Lu.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1655P - Nampt inhibitors re-sensitize MAP17 expressing pancreas tumors
Presenter: Julia Martinez Perez
Session: Poster session 22
1656P - Targeting NPC1L1 rescues anti-tumor immunity and improves immunotherapeutic efficacy in pancreatic cancer
Presenter: Houjie Liang
Session: Poster session 22
1657P - Understanding the role of SAGA and mediator in the resistance to Pdk1 deletion in PDAC
Presenter: Katarina Ondrejkova
Session: Poster session 22
1658P - Molecular subtyping of familial pancreatic ductal adenocarcinoma identifies novel pathogenic germline variants
Presenter: Julie Earl
Session: Poster session 22
1659P - The use of liquid biopsy in patients with advanced pancreatic cancer (PDAC) to guide enrollment in phase I clinical trials
Presenter: Octave Letissier
Session: Poster session 22
1660P - Squalene epoxidase promotes pancreatic cancer growth by attenuating ER stress and activating lipid rafts-regulated Src/PI3K/Akt signalling pathway
Presenter: Ruiyuan Xu
Session: Poster session 22
1661P - Precision medicine for pancreatic cancer: A clinical study validating EUS biopsies
Presenter: Joanne Lundy
Session: Poster session 22
1662P - Targeting stress granule formation as a synthetic lethality strategy for kras-induced pancreatic cancer initiation
Presenter: Patricia Santofimia
Session: Poster session 22
1663P - Role of next-generation sequencing somatic assays in patients with advanced pancreatic cancer
Presenter: Rafaela Naves
Session: Poster session 22
1664P - Italian Association for Medical Oncology (AIOM) guideline application in real-world: Multi-institutional based survey of adjuvant and first-line pancreatic ductal adenocarcinoma treatment in Italy (GARIBALDI) - survival analyses in the metastatic cohort
Presenter: Michele Reni
Session: Poster session 22